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Hematopoietic Stem Cell Transplantation in Relapsed
Acute Myelogenous Leukemia
Paul M. Armistead,1 Marcos de Lima,1 Sherry Pierce,2 Wei Qiao,3 Xuemei Wang,3
Peter F. Thall,3 Sergio Giralt,1 Farhad Ravandi,2 Hagop Kantarjian,2 Richard Champlin,1
Elihu Estey4Allogeneic hematopoietic stem cell transplantation (HSCT) is the recommended therapy for patients with
relapsed acute myelogenous leukemia (AML), despite little evidence showing a survival benefit in patients
who undergo HSCT versus chemotherapy alone. Because a prospective randomized trial addressing this
issue is unlikely, we retrospectively reviewed all patients receiving initial salvage therapy for AML at M.D.
Anderson Cancer Center between 1995 and 2004, focusing on patients undergoing HSCTor chemotherapy
without HSCTas second salvage after first salvage failed to produce complete remission (CR) (group A) and
patients in first salvage–induced CR (group B). Median survival was 5.1 months for HSCT (n584) versus 2.3
months for chemotherapy (n 5 200; P 5 .004) in group A and 11.7 months for HSCT (n 5 46) versus 5.6
months for chemotherapy (n 5 66; P\ . 001) in group B. HSCTwas associated with a survival benefit in
each of 8 subgroups defined by age\/$ 50, high-risk cytogenetics or not, and treatment in first salvage–
induced CR or second salvage, and also in 5 of 6 subgroups defined by age\/$ 50 years and duration of first
CR (CR1) (primary refractory, CR1 # 36 weeks, CR1 . 36 weeks). Our data suggest that HSCT is prefer-
able to chemotherapy alone in these patients with poor prognoses, with particular benefits noted in patients
under age 50 years.
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survivalINTRODUCTION
Acute myelogenous leukemia (AML) is the most
common acute leukemia in adults, with approximately
10,000 cases per year in the United States [1].Whereas
anthracycline 1 ara-C-containing chemotherapy is
curative in some patients, approximately 80% will
either relapse after achieving a first complete remission
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6/j.bbmt.2009.07.008induction chemotherapy [2]. Fewer than 30% of these
patients will be alive 1 year from the time of relapse or
failure of initial induction [3].
Because of the extremely poor prognosis of patients
with either relapsed or primary refractory AML,
allogeneic hematopoietic stem cell transplantation
(HSCT) is often pursued as a curative treatment strat-
egy. Several case series have reported survival rates of
25%-40% at 2 or more years after HSCT for relapsed
AML [3-5]. Factors predicting favorable outcomes
after HSCT include younger age, non–high-risk cyto-
genetics, duration of CR . 1 year, and the attainment
of CR2 after salvage chemotherapy [3-5].
These variables also are highly predictive of sur-
vival in patients with AMLwho receive salvage chemo-
therapy rather than HSCT. This similarity suggests
thatHSCT and salvage chemotherapy are qualitatively
similar, and that the favorable results reported with the
former reflect patient selection bias. The optimal basis
for testing this hypothesis would be a trial randomizing
patients with relapsed or primary refractory AML and
suitable transplant donors to receive either salvage
chemotherapy or allogeneic HSCT. Because of the1431
1432 Biol Blood Marrow Transplant 15:1431-1438, 2009P. M. Armistead et al.impracticality of this approach, we compared survival
according to whether patients in prognostic subgroups
defined by the aforementioned variables received
HSCT or chemotherapy. Our analyses focused on 2
categories of patients: (1) those receiving HSCT or
chemotherapy as second salvage therapy, that is, after
an initial (first salvage) chemotherapy regimen failed
to produce CR for relapsed or primary refractory
AML, and (2) those receiving HSCT or chemotherapy
as postremission therapy after first salvage chemother-
apy produced CR in relapsed or primary refractory
AML.PATIENTS AND METHODS
Patient Characteristics
The starting point for our analyses was the 599
patients with relapsed or primary refractory AML,
without inv(16), t(8;21), or t(15;17), who were treated
by the Department of Leukemia at theM.D. Anderson
Cancer Center between 1995 and 2004. After exclud-
ing the 67 patients who died during their first salvage
therapy and the 42 who underwent HSCT as their first
salvage therapy, 490 patients remained (Figure 1).
Their median age was 59 years, and median durationFigure 1. Flow chart of patient treatments. Of 599 evaluable patients, 67 died
salvage therapy (both shown in gray boxes). These groups were not used in th
tients achievedCR, and 378 did not. After first salvage therapy, 94 patients did n
excluded from further analysis, leaving 396 patients for analysis.of CR1 was 22 weeks. High-risk cytogenetics (defined
as25,27, or complex karyotype with 3 or more cyto-
genetic abnormalities) were present in 290 of these pa-
tients (59%). At the time of first salvage, the median
creatinine value was 0.9 and the median total bilirubin
value was 0.6, with no significant differences between
patients who ultimately underwent HSCT and those
who did not. The first salvage regimen contained
high- or intermediate-dose ara-C in 383 patients
(78%). Of the 490 patients, 112 (23%) achieved CR
with first salvage chemotherapy and 378 did not.
This low CR rate primarily results from to the ex-
tremely poor prognosis of the group of patients being
studied, particularly their median CR1 of\1 year [6].
Ninety-four of the 378 patients who did not achieve
CR with first salvage therapy received no treatment
(HSCT or chemotherapy) after first salvage. These pa-
tients were excluded from subsequent analyses, leaving
396 patients (112 who achieved CR and 284 who did
not) in our final data set. These 396 patients included
46 who received HSCT in first salvage–induced CR,
66 who received chemotherapy in first salvage–
induced CR, 84 who received HSCT as second salvage
after failure of first salvage, and 200 who received che-
motherapy as second (and all subsequent) salvage after
failure of first salvage. Thus, 42% of the patients whoduring first salvage chemotherapy and 42 underwent HSCTas their first
is analysis. The remaining 490 patients were evaluable; of these, 112 pa-
ot undergo further treatment (shown in gray box) andwere subsequently
Table 1. Baseline HSCT Characteristics
1995-1999 (n 5 63) 2000-2004 (n 5 67)
Conditioning, n (%)
Reduced intensity 28 (44%) 30 (45%)
Fludarabine/melphalan 10 (16%) 14 (21%)
Busulfan/fludarabine 1 (1%) 16 (24%)
Miscellaneous 17 (27%) 0 (0%)
Ablative 35 (56%) 37 (55%)
TBI-containing 15 (24%) 2 (3%)
Busulfan/cyclophosphamide 20 (32%) 12 (18%)
Busulfan/fludarabine 0 (0%) 23 (34%)
Stem cell source, n (%)
Matched related 42 (67%) 30 (45%)
Matched unrelated 13 (21%) 31 (46%)
Mismatched related 7 (11%) 3 (5%)
Mismatched unrelated 0 2 (3%)
Cord blood 1 (1%) 1 (1%)
HSCT indicates hematopoietic stem cell transplantation; TBI, total body
irradiation.
The conditioning regimens and stem cell sources for the 130 allogeneic
transplants performed after first salvage are shown for the periods
1995-1999 and 2000-2004. Over this time frame, more matched unre-
lated donor transplantations were performed. The conditioning regi-
mens used also changed, with fewer TBI-containing regimens used,
and the majority of transplants performed with busulfan/fludarabine-
based conditioning.





(n 5 130) P value
Age, years, mean (SD) 59.5 (14.5) 44.4 (14.4) < .0001
Duration of CR1, weeks, mean (SD) 31.1 (39.8) 41.4 (43.2) .0004
Delay time, weeks, mean (SD) 15.4 (23.2) 21.6 (36.6) < .0001
Cytogenetics, n (%)
Unfavorable 224 (62.2%) 66 (50.8%)
Intermediate 136 (37.8%) 64 (49.2%) .03
First salvage–induced CR, n (%)
Non-CR 293 (81.4%) 84 (64.6%)
CR 67 (18.6%) 46 (35.4%) .0002
HSCT indicates hematopoietic stem cell transplantation; CR1, first com-
plete remission.
For all evaluable patients treated for relapsed AML, statistically signifi-
cant (P < .05) differences in age, CR1, and time between first salvage
and subsequent treatment, proportion of patients with unfavorable
cytogenetics, and treatment performed in first salvage–induced CR
were observed between the HSCTand non-HSCT cohorts. These fac-
tors were included in the subsequent multiple-subgroup analyses.
Wilcoxon’s test for continuous variables or Fisher’s exact test for
categorical variables.
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in this CR, whereas 22% of those in whom first salvage
did not produce CR received HSCT as second salvage.
We compared survival from the time of initiation of
postremission therapy in patients who did and did
not receive HSCT and survival from start of second
salvage in patients who did and did not receive
HSCT as second salvage.
Table 1 lists the conditioning regimens and stem
cell sources for the 130 patients (33% of the 396)
who underwent HSCT. The 67 patients who under-
went HSCT between 2000 and 2004 were more likely
to receive matched unrelated donor transplants and
less likely to receive total body irradiation (TBI).
Despite these differences, there was no difference in
overall survival (OS) between patients receiving unre-
lated donor transplants and those receiving related do-
nor transplants in both the first salvage–induced CR
subgroup (P 5 .48) and the second salvage subgroup
(P 5 .7). The 130 patients who underwent HSCT
were a mean of 15 years younger than the 266 patients
who did not undergo HSCT, were more likely to re-
ceive HSCT in CR rather than as second salvage, and
had on average a 10-week longer duration of CR1
and a 6-week longer interval from first salvage to the
next therapy (HSCT or chemotherapy) (Table 2).Statistical Methods
Covariates were compared between theHSCT and
chemotherapy groups using a Wilcoxon-Mann-Whit-
ney test for quantitative variables [7] or Fisher’s exact
test [8] for discrete variables. Unadjusted survival time
probabilities were estimated using the method ofKaplan and Meier [9], and between-group survival time
comparisons were made using the log-rank test [10].
Analysis
Initial Kaplan-Meier survival analysis showed statis-
tically longer survival in patients receiving HSCT (see
below). Although multivariate analyses would typically
be done to examine whether this difference reflected
treatment (HSCTor chemotherapy) rather than abetter
underlying prognosis, multivariate analyses were com-
plicated by the strong associations between treatment
and the covariates given in Table 2. The strength of
these associations was such that, for example, a longer
time from first salvage to subsequent therapy (‘‘delay
time’’) was essentially collinear with HSCT (P\ .001).
In these circumstances, the problem of collinearity
makes multivariate regression models numerically un-
stable and their results unreliable. Rather than fitting
such unreliable survival time regression models, we in-
stead stratified the patients into subgroups. Within
each subgroup, we calculated Kaplan-Meier survival es-
timates and performed log-rank tests to compare OS
between HSCT and non-HSCT groups [9,10]. We
also performed an overall comparison using a stratified
log-rank test [11].RESULTS
Unstratified Survival for Patients with Relapsed
or Primary Refractory AML by Treatment Type
A log-rank test performed on the entire 396 pa-
tient cohort and Kaplan-Meier estimates revealed
longer survival in patients who underwent HSCT
(P\ .0001) (Figure 2A). This was true both in patients
Figure 2. Overall survival of patient cohorts. Kaplan-Meier survival
probability curves were generated to evaluate overall survival probabil-
ity for the entire evaluable cohort. A, Overall survival for the entire co-
hort according to treatment modality. B, Overall survival in patients who
underwent HSCT in first salvage–induced CR. C, Overall survival in pa-
tients who underwent HSCTas second salvage. In all 3 analyses, a statis-
tically significant survival advantage was observed in the HSCT cohorts.
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had not (Figures 2B and C). In the CR group, median
survival from the initiation of postremission therapy
was 11.7 months in the HSCT group and 5.6 months
in the chemotherapy group (P\ .001). For patients
receiving HSCT or chemotherapy as second salvage,
median survival from the start of second salvage was
5.1 months in the HSCT group and 2.3 months in
the chemotherapy group (P 5 .004).Subgroup Analysis by Age, Cytogenetics, and
First Salvage–Induced CR Status
Given the high degree of collinearity between
treatment and nontreatment covariates (Table 2),
we used a multiple-subgroup analysis strategy. Be-
cause of the limited number of patients, a subgroup
analysis accounting for all of the covariates listed in
Table 2 was not feasible, producing 32 distinct sub-
groups. Thus, we first divided the 396-patient cohort
(Figure 1) into 8 subgroups based on 3 dichotomous
variables known to be predictive of survival in these
patients: age (\ 50 vs $ 50 years), cytogenetics (in-
termediate vs high risk), and achievement of CR after
first salvage therapy (yes vs no). The resulting 8 Ka-
plan-Meier survival curves are shown in Figure 3, and
their corresponding median survival times for
patients who received HSCT or chemotherapy are
given in Table 3. HSCT had a longer median survival
in all of the 8 subgroups. These results were statisti-
cally significant (P\ .05) in 4 of the 8 subgroups (2 of
the 4 subgroups with more than the median subgroup
size of 35 patients and 2 of the 4 subgroups with # 35
patients). Application of a stratified log-rank test to
all 8 subgroups showed that survival was significantly
longer in the entire HSCT treatment cohort
compared with the entire chemotherapy-alone group
(P\ .0001).
Subgroup Analysis by Age and Duration of CR1
We performed additional analyses to evaluate sur-
vival in the 6 subgroups defined by age (\ 50 vs $ 50
years) and CR1 duration (primary refractory, CR1 du-
ration# 36 weeks, CR1 duration. 36 weeks), with 36
weeks the overall median duration of CR1. The result-
ing 6 survival curves are shown in Figure 4, and associ-
ated OS data are given in Table 4. Median survival
with HSCT was longer in 5 of the 6 groups, the excep-
tion being a 1-week advantage for chemotherapy in pa-
tients aged$ 50 years with a first salvage–induced CR
duration of\36 weeks. The survival advantage seen in
the HSCT groups was statistically significant in 3 of
the 6 subgroups, with a nonsignificant survival
advantage seen in the patients aged $ 50 years, who
were either primary refractory or had a CR1 duration
of . 36 weeks.DISCUSSION
For at least the last 30 years, physicians have de-
bated the relative merits of allogeneic HSCT versus
chemotherapy without HSCT in various scenarios, in-
cluding CR produced by initial AML treatment, first
salvage, CR produced by first salvage, and second sal-
vage. We have examined the latter 2 scenarios here.
The length of the debate reflects the relatively small
medical (as opposed to statistical) differences between
Figure 3. First multiple-subgroup analysis. Kaplan-Meier survival probability curves were generated for subgroups based on remission status following
first salvage, age, and cytogenetics as described in the heading for each curve. The letter heading for each curve matches the prognostic factors and
survival data described in Table 3.
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addressing the question through a trial that random-
izes patients with identified donors between HSCT
and chemotherapy. As an alternative to randomization,
many studies have used multivariate analyses to inves-
tigate whether, after accounting for known prognostic
covariates, one treatment was superior to another. But,
the issue of collinearity between treatments (HSCT vschemotherapy) and patient covariates known to
strongly predict survival time made us hesitant to carry
outmultivariate regression analyses here, prompting us
to compare HSCT and chemotherapy in each of sev-
eral ‘‘comparable’’ subgroups using log-rank tests and
Kaplan-Meier plots within each subgroup, with com-
parability based on the covariates listed in Table 2.
These simple analyses suggest thatHSCT is preferable
Table 3. Comparison of Overall Survival between HSCT and Non-HSCT Cohorts by Multiple-Subgroup Analyses According to
Age, Cytogenetics, and First Salvage–Induced CR Status
Median Survival Time (95% Confidence Interval)
Group n HSCT Chemotherapy P value
A: age <50, intermediate cytogenetics, first salvage– induced CR 28 17.25 (8.29, NA) 3.12 (2.36, NA) .004
B: age < 50, intermediate cytogenetics, no first salvage–induced CR 35 5.15 (4.16, 18.03) 2.36 (1.41, 5.15) .001
C: age < 50, unfavorable cytogenetics, first salvage– induced CR 17 11.08 (10.43, NA) 4.54 (1.15, NA) .60
D: age < 50, unfavorable cytogenetics, no first salvage–induced CR 60 5.05 (3.90, 8.69) 2.33 (1.51, 3.44) .003
E: age $ 50, intermediate cytogenetics, first salvage– induced CR 29 13.5 (1.84, NA) 8.1 (4.85, 17.9) .68
F: age $ 50, intermediate cytogenetics, no first salvage–induced CR 75 6.26 (5.34, 23.87) 2.66 (2.20, 3.48) .006
G: age $ 50, unfavorable cytogenetics, first salvage–induced CR 38 5.21 (4.39, NA) 4.92 (3.25, 7.9) .43
H: age $ 50, unfavorable cytogenetics, no first salvage–induced CR 114 2.62 (2.07, 8.46) 2.00 (1.48, 2.95) .09
NA indicates not applicable; CR, complete response; HSCT, hematopoietic stem cell transplantation.
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receive second salvage therapy for active AML or in
whomfirst salvage therapy producedCR, including pa-
tients\ and $ the age of 50 years, with high-risk or
other cytogenetics, and with varying durations of first
CR. It should be noted, however, that the survival ben-Figure 4. Second multiple-subgroup analysis. Kaplan-Meier survival probabilit
factors of age and duration of CR1, as described in the heading for each curve
survival data described in Table 4.efit for patient cohorts aged $ 50 years did not reach
statistical significance (P\ .05) in most circumstances.
Although the survival benefit in this older population is
less clear in this study, recent reports on the efficacy of
reduced-intensity conditioning (RIC) in the elderly
may point to improved outcomes in this group,y curves were generated for subgroups based on the known prognostic
. The letter heading for each curve matches the prognostic factors and
Table 4. Comparison of Overall Survival between HSCTand
Non-HSCT Cohorts by Multiple-Subgroup Analyses Accord-
ing to Age and Duration of CR1
Median Survival Time
(95% Confidence Interval)
Group n HSCT Chemotherapy P value
A: age < 50,CR1
duration > 36 weeks
48 13.54 (8.69, 31.2) 5.15 (4.0, 16.6) .03
B: age < 50,CR1
duration # 36 weeks
57 5.05 (4.29, 10.43) 2.88 (1.44, 3.77) .0005
C: age < 50,CR1
duration 0 weeks
35 5.71 (4.59, NA) 1.84 (1.34, 3.15) .0002
D: age $ 50,CR1
duration > 36 weeks
100 6.13 (3.93, 8.98) 3.48 (2.62, 6.0) .17
E: age $ 50,CR1
duration # 36 weeks
85 2.47 (1.9, NA) 2.66 (1.97, 3.48) .05
F: age $ 50,CR1
duration 0 weeks
71 5.85 (4.39, NA) 2.26 (1.9, 3.57) .15
NA indicates not applicable; CR1, first complete response; HSCT,
hematopoietic stem cell transplantation.
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of whom underwent HSCT before 2000 [12].
An important question is whether the covariates
listed inTable 2 were in fact prognostic in our patients,
as reported in other series. In general, this appears to
be the case. For example, a comparison of high-risk
and non–high-risk cytogenetics in otherwise similar
groups (groups A vs C, B vs D, E vs G, and F vs H in
Table 3) indicates that high-risk cytogenetics was
strongly associated with worse survival regardless of
whether patients received HSCT or chemotherapy.
Patients did better when treated in first salvage–
induced CR rather than in second salvage (groups A
vs B, C vs D, E vs F, and G vs H), independent of treat-
ment, as they did when their duration of CR1 was. 36
weeks rather than\36 weeks (groups A vs B and D vs
E in Table 4).
The time from first salvage therapy until next
treatment (ie, delay time) strongly correlated with
treatment type (HSCT vs chemotherapy), and it is
possible that the longer delay time in the HSCT group
led to the selection of patients with a generally more
indolent AML. Our survival analyses minimized the
effect of delay time by measuring survival from the
time of subsequent therapy. Regardless, the clinical
significance of delay time likely is minor when the sur-
vival outcomes for patients undergoing HSCT in CR
are compared with the outcomes for all other groups
(eg, HSCT not in CR, no HSCT). As a whole, our
data support an urgency in proceeding to allogeneic
HSCT as soon as possible to either perform transplan-
tation while the patient is in CR or to at least perform
transplantation while the patient has minimal disease
burden, and toxicity from salvage chemotherapy.
This approach is often complicated by unrelated donor
searches, which can increase the time to subsequent
therapy by months. Given the extremely poor out-
comes for all of the non-HSCT patient cohorts inour study, alternative donor strategies should be inves-
tigated to reduce the time to transplantation and
hopefully increase the percentage of transplantations
performed in CR [13,14].
Differences in outcome such as those shown in Fig-
ure 2may, of course, reflect not only the effects of treat-
ment or of known prognostic covariates (Table 2), but
also differences in unknowable or unquantifiable fac-
tors. Principal among these factors in our patients was
selection bias, operating such that patients with donors
might not have undergone transplantation out of fear
that they would do poorly. This possibility is typically
addressed by comparing outcomes in patients with
andwithoutdonors regardless ofwhether the former re-
ceived HSCT. The retrospective nature of our analysis
did not permit a donor versus no donor comparison;
however, the fact that 33%ofourpatients (130/396) un-
derwentHSCT, including42%of those infirst salvage–
induced CR and 22% as second salvage, suggests that
the effect of selection bias was not overwhelming, par-
ticularly given that the use of unrelated donors was
not as common during the study period as it is today.
Using the M.D. Anderson database allowed us
to capture the outcome of chemotherapy without
HSCT in a well-defined group of patients. Thus, this
study is the first to compare survival in patients with
AML in first salvage–induced CR or about to receive
second salvage for active AML according to whether
they received HSCT or chemotherapy without
HSCT. Despite the aforementioned limitations of
a retrospective study, our data suggest that HSCT is
the preferable option in the great majority of these pa-
tients, particularly those aged\ 50 years and judged
healthy enough to undergo HSCT. Indeed, the
extremely poor outcomes for patients aged\50 years
who did not undergo HSCT, considered in light of
recent reports on the efficacy of cord blood transplan-
tation, would suggest that this strategy should also be
considered [13,14]. Nonetheless, the prognosis of
patients with relapsed AML remains poor, and novel
investigational approaches should still be vigorously
pursued in these patients.ACKNOWLEDGMENTS
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